Cybin D/B/A Helus Pharma
HELPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCybin D/B/A Helus Pharma operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. At a $744.6M market cap, Cybin D/B/A Helus Pharma ranks as a small-cap company within healthcare. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
Market Cap
$744.6M
Beta
0.54
P/E (TTM)
—
P/E (Fwd)
-5.79
EPS (TTM)
$-4.15
EPS (Fwd)
$-1.76
ROE
-86.9%
ROA
-44.4%
Cash
$166.4M
Total Debt
$0
Free CF
-$82.4M
52W Change
56.5%
Annual Financials
Cash vs Debt
Where HELP stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, HELP finished 34.81% above its 150-day moving average ($7.70) and 37.48% above its 200-day moving average ($7.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HELP overbought or oversold?
At the October 15, 2026 close, HELP's RSI(14) was 28.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cybin D/B/A Helus Pharma reports $166.4M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$82.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -86.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
HELP's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HELP.